Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Thomas A. Musliner"'
Autor:
Robert P. Giugliano, MD, SM, Baris Gencer, MD, Stephen D. Wiviott, MD, Jeong-Gun Park, PHD, Charles S. Fuchs, MD, MPH, Wolfram Goessling, MD, PHD, Thomas A. Musliner, MD, Andrew M. Tershakovec, MD, MPH, Michael A. Blazing, MD, Robert Califf, MD, Christopher P. Cannon, MD, Eugene Braunwald, MD
Publikováno v:
JACC. CardioOncology, Vol 2, Iss 3, Pp 385-396 (2020)
Background: An increased risk of malignancy was reported with simvastatin/ezetimibe in 1,873 patients in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial. Objectives: The purpose of this study was to clarify this unexpected finding in a
Externí odkaz:
https://doaj.org/article/e7361de870fb47f0bb0bb5a141f13c54
Autor:
Stephen D Wiviott, Robert P Giugliano, Michael A Blazing, Christopher P Cannon, Jing Zhou, Sabina A Murphy, Andrew M Tershakovec, Thomas A Musliner, Braunwald Eugene
Publikováno v:
Circulation. 132
Background: Statins have been demonstrated to reduce ischemic stroke. Intensive therapy with ezetimibe/simvastatin (E/S) in IMPROVE-IT significantly reduced the occurrence of cardiovascular events in patients post ACS compared to placebo/simvastatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78246070ccb0084e0c630b28757baa0b
https://doi.org/10.1161/circ.132.suppl_3.19694
https://doi.org/10.1161/circ.132.suppl_3.19694
Autor:
Tatu A. Miettinen, Kalevi Pyörälä, Anders G. Olsson, Thomas A. Musliner, Thomas J. Cook, Ole Faergeman, Kåre Berg, Terje Pedersen, John Kjekshus, for the Scandinavian Simvastatin Study Group
Publikováno v:
Circulation. 96:4211-4218
Background The Scandinavian Simvastatin Survival Study (4S) demonstrated pronounced reductions in mortality and major coronary events in a cohort of patients with established coronary heart disease (CHD). The present study provides a detailed, post h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef2cb0105fef417224885d75dfb6165e
https://doi.org/10.1161/01.cir.96.12.4211
https://doi.org/10.1161/01.cir.96.12.4211
Autor:
Trudy M. Forte, Long, Thomas A. Musliner, Elaine L. Gong, Ronald M. Krauss, Alex V. Nichols, Patricia J. Blanche
Publikováno v:
Journal of Lipid Research, Vol 32, Iss 6, Pp 917-933 (1991)
Incubation of low (LDL), intermediate (IDL), or very low density lipoproteins (VLDL) with palmitic acid and either high density lipoproteins (HDL), delipidated HDL, or purified apolipoprotein (apo) A-I resulted in the formation of lipoprotein particl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::698652474c888612d039c1825b55da96
http://www.sciencedirect.com/science/article/pii/S0022227520419893
http://www.sciencedirect.com/science/article/pii/S0022227520419893
Autor:
Christopher P, Cannon, Robert P, Giugliano, Michael A, Blazing, Robert A, Harrington, John L, Peterson, Christine McCrary, Sisk, John, Strony, Thomas A, Musliner, Carolyn H, McCabe, Enrico, Veltri, Eugene, Braunwald, Robert M, Califf, Andrew, Tonkin
Publikováno v:
American heart journal. 156(5)
Background Reduction in low-density lipoprotein cholesterol (LDL-C) improves clinical outcomes in patients with chronic coronary artery disease and acute coronary syndromes (ACSs). The combination of ezetimibe/simvastatin produces greater reductions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6a673c9ce8289577289d1e05f02f2fa
https://pubmed.ncbi.nlm.nih.gov/24917645
https://pubmed.ncbi.nlm.nih.gov/24917645
Autor:
Terje R, Pedersen, Anders G, Olsson, Ole, Faergeman, John, Kjekshus, Hans, Wedel, Kåre, Berg, Lars, Wilhelmsen, Torben, Haghfelt, Gudmundur, Thorgeirsson, Kalevi, Pyörälä, Tatu, Miettinen, Bjørn, Christophersen, Jonathan A, Tobert, Thomas A, Musliner, Thomas J, Cook
Publikováno v:
Atherosclerosis. Supplements. 5(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fbfd259be5d060f2929d68abf0cb3232
https://pubmed.ncbi.nlm.nih.gov/15531282
https://pubmed.ncbi.nlm.nih.gov/15531282
Autor:
Thomas A Musliner, Pedro Mata, Michael Melino, Meehyung Cho, Barry Gumbiner, Claude Gagné, Katherine Quinto, Harold E. Bays, Stuart R. Weiss
Publikováno v:
The American journal of cardiology. 90(10)
Ezetimibe is a lipid-lowering drug that inhibits the intestinal absorption of dietary and biliary cholesterol by blocking passage across the intestinal wall. The efficacy and safety of adding ezetimibe to ongoing statin therapy in patients with prima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0300cacc417370e8815ea758840c51b
https://pubmed.ncbi.nlm.nih.gov/12841712
https://pubmed.ncbi.nlm.nih.gov/12841712
Publikováno v:
Journal of Lipid Research, Vol 32, Iss 6, Pp 903-915 (1991)
Plasma from individual human subjects is known to contain multiple discrete subpopulations of low (LDL) and intermediate (IDL) density lipoproteins that differ in particle size and density. The metabolic origins of these subpopulations are unknown. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77a6a57ba727dffb74ce472262170c22
https://pubmed.ncbi.nlm.nih.gov/1940623
https://pubmed.ncbi.nlm.nih.gov/1940623
Autor:
Gerd Assmann, Frank Kannenberg, Dena R. Ramey, Thomas A. Musliner, Stephen W. Gutkin, Enrico P. Veltri
Publikováno v:
Current Medical Research & Opinion; Jan2008, Vol. 24 Issue 1, p249-259, 11p
Autor:
Thomas A. Musliner, Eve C. Church, Marguerite J. Kingston, Peter N. Herbert, Richard S. Shulman
Publikováno v:
Proceedings of the National Academy of Sciences. 74:5358-5362
Apolipoprotein C-II (apoC-II) is a small protein found associated with the plasma lipoproteins. It serves a unique function in the activation of the enzyme lipoprotein lipase (triacylglycerol acyl-hydrolase, EC 3.1.1.3). ApoC-II contains a single arg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c06924bd354af11ec5927bfebaa4321
https://doi.org/10.1073/pnas.74.12.5358
https://doi.org/10.1073/pnas.74.12.5358